Literature DB >> 8958044

Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci.

E R Brandt1, W A Hayman, B Currie, J Carapetis, Y Wood, D C Jackson, J Cooper, W D Melrose, A J Saul, M F Good.   

Abstract

This study demonstrates the presence of epitope-specific opsonic human antibodies in a population living in an area endemic for group A streptococci (GAS) infection. Antibodies recognizing a conserved C-terminal region epitope (p145, sequence in single letter amino acids: LRRDLDASREAKKQVEKALE) of the M protein of GAS were isolated from human patients by affinity chromatography and were shown to be of the immunoglobulin G1 (IgG1) and IgG3 subclasses. These antibodies could reduce the number of colonies of serotype 5 GAS in an in vitro opsonization assay by 71-92%, compared with an equal amount of IgG from control adult donors living in non-endemic areas and without antibodies to p145. Addition of the peptide, p145, completely inhibited this opsonization. Indirect immunofluorescence showed that p145-specific antibodies were capable of binding to the surface of M5 GAS whereas control IgG did not. Using chimeric peptides, which contain overlapping segments of p145, each 12 amino acids in length, inserted into a known helical peptide derived from the DNA binding protein of yeast, GCN4, we have been able to further define two minimal regions within p145, referred to as pJ2 and pJ7. These peptides, pJ2 and pJ7, were able to inhibit opsonization by p145 specific antibodies. Finally, we have observed an association between the age-related development of immunity to GAS and the acquisition of antibodies to the conserved epitope, p145, raising the possibility of using this epitope as a target in a prophylactic vaccine administered during early childhood.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958044      PMCID: PMC1456558          DOI: 10.1046/j.1365-2567.1996.d01-754.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  21 in total

1.  Acute rheumatic fever and rheumatic heart disease in a rural central Australian aboriginal community.

Authors:  R E Brennan; M S Patel
Journal:  Med J Aust       Date:  1990-09-17       Impact factor: 7.738

2.  Identification of mononuclear cells and T cell subsets in rheumatic valvulitis.

Authors:  E Kemeny; T Grieve; R Marcus; P Sareli; J B Zabriskie
Journal:  Clin Immunol Immunopathol       Date:  1989-08

3.  Type-specific inhibition of preopsonization versus immunoprecipitation by Streptococcal M proteins.

Authors:  E H Beachey; M Cunningham
Journal:  Infect Immun       Date:  1973-07       Impact factor: 3.441

4.  Acquisition of group A streptococcal M protein antibodies.

Authors:  R W Quinn; R Vander Zwaag; P N Lowry
Journal:  Pediatr Infect Dis       Date:  1985 Jul-Aug

5.  Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes.

Authors:  D Bessen; V A Fischetti
Journal:  J Immunol       Date:  1990-08-15       Impact factor: 5.422

6.  The human antibody response to streptococcal C5a peptidase.

Authors:  S P O'Connor; D Darip; K Fraley; C M Nelson; E L Kaplan; P P Cleary
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

7.  Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci.

Authors:  D Bessen; V A Fischetti
Journal:  Infect Immun       Date:  1988-10       Impact factor: 3.441

8.  Inositol trisphosphate-induced calcium release and contraction in vascular smooth muscle.

Authors:  A V Somlyo; M Bond; A P Somlyo; A Scarpa
Journal:  Proc Natl Acad Sci U S A       Date:  1985-08       Impact factor: 11.205

9.  Protective immunogenicity and T lymphocyte specificity of a trivalent hybrid peptide containing NH2-terminal sequences of types 5, 6, and 24 M proteins synthesized in tandem.

Authors:  E H Beachey; J M Seyer; J B Dale
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

10.  Differentiation of group A streptococci with a common R antigen into three serological types, with special reference to the bactericidal test.

Authors:  R C LANCEFIELD
Journal:  J Exp Med       Date:  1957-10-01       Impact factor: 14.307

View more
  22 in total

1.  Protective and nonprotective epitopes from amino termini of M proteins from Australian aboriginal isolates and reference strains of group A streptococci.

Authors:  E R Brandt; T Teh; W A Relf; R I Hobb; M F Good
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

Review 2.  Strategies in the development of vaccines to prevent infections with group A streptococcus.

Authors:  Michael F Good; Michael R Batzloff; Manisha Pandey
Journal:  Hum Vaccin Immunother       Date:  2013-06-28       Impact factor: 3.452

3.  Host Pathways of Hemostasis that Regulate Group A Streptococcus pyogenes Pathogenicity.

Authors:  Victoria A Ploplis; Francis J Castellino
Journal:  Curr Drug Targets       Date:  2020       Impact factor: 3.465

Review 4.  Advances in potential M-protein peptide-based vaccines for preventing rheumatic fever and rheumatic heart disease.

Authors:  Michael R Batzloff; Manisha Pandey; Colleen Olive; Michael F Good
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

5.  In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.

Authors:  Therese Nordström; Jessica Malcolm; Graham Magor; Michael F Good; Michael R Batzloff
Journal:  Clin Vaccine Immunol       Date:  2012-10-17

6.  Preclinical immunogenicity and safety of a Group A streptococcal M protein-based vaccine candidate.

Authors:  Michael R Batzloff; Anne Fane; Davina Gorton; Manisha Pandey; Tania Rivera-Hernandez; Ainslie Calcutt; Grace Yeung; Jon Hartas; Linda Johnson; Catherine M Rush; James McCarthy; Natkunam Ketheesan; Michael F Good
Journal:  Hum Vaccin Immunother       Date:  2016-08-19       Impact factor: 3.452

7.  Recurrent sepsis caused by Streptococcus pyogenes.

Authors:  Magnus Rasmussen
Journal:  J Clin Microbiol       Date:  2011-02-23       Impact factor: 5.948

8.  Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.

Authors:  Thomas A Penfound; Edna Y Chiang; Elwaleed A Ahmed; James B Dale
Journal:  Vaccine       Date:  2010-05-21       Impact factor: 3.641

Review 9.  Pathogenesis of group A streptococcal infections.

Authors:  M W Cunningham
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

10.  Correlation between bioluminescence and bacterial burden in passively protected mice challenged with a recombinant bioluminescent M49 group A streptococcus Strain.

Authors:  Meru Sheel; Manisha Pandey; Michael F Good; Michael R Batzloff
Journal:  Clin Vaccine Immunol       Date:  2009-11-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.